USPTO Examiner GANGLE BRIAN J - Art Unit 1645

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18871201USE OF AKKERMANSIA MUCINIPHILA IN PREPARATION OF PHARMACEUTICAL COMPOSITION OR HEALTH CARE PRODUCT COMPOSITION FOR IMPROVING METABOLIC SYNDROMEDecember 2024July 2025Allow710NoNo
18738464Probiotic Method and Composition for Maintaining a Healthy Vaginal MicrobiomeJune 2024January 2025Allow810YesNo
18606817ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOFMarch 2024June 2025Allow1511NoNo
18605436GLYCOSYLATED COMP PILIN VARIANTS, METHODS OF MAKING AND USES THEREOFMarch 2024November 2025Allow2011NoNo
18601211COMPLEX OF BOTULINUM NEUROTOXIN E AND ITS BINDING PROTEIN AS A FORMULATION WITH ENHANCED POTENCYMarch 2024March 2025Allow1210YesNo
18581838USE OF AKKERMANSIA IN THE TREATMENT OF ORAL DISEASESFebruary 2024August 2025Allow1820YesNo
18580997NOVEL LACTOBACILLUS PARACASEI ATG-E1 STRAIN OR COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING RESPIRATORY DISEASEJanuary 2024March 2026Allow2610NoNo
18413961TREATMENT OR PREVENTION OF GASTROINTESTINAL DYSBIOSISJanuary 2024October 2025Abandon2111NoNo
18412769PROBIOTIC MOLECULES FOR REDUCING PATHOGEN VIRULENCEJanuary 2024July 2025Abandon1811NoNo
18404430SILICIFIED CELL REPLICAS, METHODS OF MAKING, AND METHODS OF USINGJanuary 2024June 2025Allow1710NoNo
18538429COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIESDecember 2023October 2025Allow2311NoNo
18537398METHODS AND MATERIALS FOR USING RUMINOCOCCUS GNAVUS OR CLOSTRIDIUM SPOROGENES TO TREAT GASTROINTESTINAL DISORDERSDecember 2023November 2024Allow1110NoNo
18535722TOPICAL APPLICATION TO TREAT ACNE VULGARISDecember 2023November 2024Allow1110NoNo
18525109PEPTIDES DERIVED FROM ACINETOBACTER BAUMANNII AND THEIR USE IN VACCINATIONNovember 2023December 2025Allow2411NoNo
18519981Combination Method For Treating Or Preventing Childhood Atopic DiseaseNovember 2023July 2024Allow711NoNo
18508430BACILLUS SUBTILIS PROBIOTICS AND METHODS OF USE FOR IMPROVING IMMUNE FUNCTION, HORMONAL STATUS, AND PHYSICAL PERFORMANCENovember 2023March 2026Allow2810NoNo
18503294EXPEC GLYCOCONJUGATE VACCINE FORMULATIONSNovember 2023October 2025Allow2310YesNo
18502728CELL-BASED METHOD FOR DETERMINING AN ACTIVITY OF BOTULINUM TOXINNovember 2023November 2024Abandon1310NoNo
18467682Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated ProteinsSeptember 2023December 2024Allow1510NoNo
18235686Method and System for Modulating an Individual's Skin MicrobiomeAugust 2023January 2024Allow510YesNo
18234544Method and System for Addressing Adverse Effects on the Oral Microbiome and Restoring Gingival Health Caused by Sodium Lauryl Sulphate ExposureAugust 2023January 2024Allow510NoNo
18234132Method and System to Modify an Individual's Gut-Brain Axis to Provide Neurocognitive ProtectionAugust 2023January 2024Allow510NoNo
18232980Probiotic Composition and Method for Controlling Excess Weight, Obesity, NAFLD and NASHAugust 2023December 2023Allow410NoNo
18446970MICROORGANISMS ENGINEERED TO REDUCE HYPERPHENYLALANINEMIAAugust 2023August 2024Allow1210NoNo
18269878BACTERIAL STRAIN BELONGING TO THE GENUS CHRISTENSENELLA, AND COMPOSITIONSJuly 2023March 2026Allow3210NoNo
18339723ENHANCING IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATESJune 2023January 2025Allow1910NoNo
18212253Bifidobacterium brevis and its application in preventing or alleviating psoriasis thereofJune 2023January 2026Allow3120NoNo
18337354COMPOSITION FOR THE TREATMENT OF ANTIBODY DEFICIENCIESJune 2023August 2024Allow1410NoNo
18256430COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISEASES OR PSYCHIATRIC DISEASES COMPRISING VESICLES DERIVED FROM SPHINGOMONAS BACTERIAJune 2023March 2026Abandon3310NoNo
18202842MULTIVALENT PNEUMOCOCCAL VACCINESMay 2023April 2025Allow2210NoNo
18320834GLOBAL GENE REGULATORS (GGR) AS VACCINE CANDIDATES AGAINST PARATUBERCULOSISMay 2023August 2024Allow1501NoNo
18319086COMPOSITIONS AND METHODS FOR TREATING CHOLESTATIC DISEASEMay 2023September 2025Abandon2811NoNo
18252206A MYCOBACTERIUM FOR USE IN CANCER THERAPYMay 2023March 2026Allow3410NoNo
18143399Modulation of an Individual's Gut Microbiome to Address Osteoporosis and Bone DiseaseMay 2023December 2023Allow720NoNo
18311691COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER COMPRISING MIXED STRAIN OF PROBIOTICSMay 2023October 2025Allow2900NoNo
18141270PEPTIDES AND ANTIBODIES FOR THE REMOVAL OF BIOFILMSApril 2023September 2024Allow1711NoNo
18305948Novel Polysaccharide and Uses ThereofApril 2023September 2024Allow1711NoNo
18130946Probiotic to Enhance an Individual's Skin MicrobiomeApril 2023July 2023Allow410YesNo
18129791System And Method For The Detection And Prevention of Leukemia And LymphomaMarch 2023July 2024Allow1521YesNo
18178847Topical Application of CRISPR-Modified Bacteria to Treat Acne VulgarisMarch 2023July 2023Allow510NoNo
18184869Tuberculosis Antigen CassettesMarch 2023July 2024Allow1710NoNo
18184711BACILLUS BACTERIUM, INTERLEUKIN-22 PRODUCTION INDUCING AGENT, SKIN BARRIER FUNCTION ENHANCING AGENTMarch 2023December 2024Allow2120YesNo
18044728CONJUGATE AND PHOTOIMMUNOTHERAPYMarch 2023January 2026Allow3510YesNo
18178602VACCINATION AGAINST DIABETES, OBESITY AND COMPLICATIONS THEREOFMarch 2023February 2026Abandon3601NoNo
18022763USE OF ADLERCREUTZIA BACTERIA FOR THE TREATMENT OF INFLAMMATORY DISEASESFebruary 2023January 2026Allow3510NoNo
18019383RECOMBINANT BACTERIA FOR PRODUCTION OF D-LACTATE AND/OR L-LACTATE AND USES THEREOFFebruary 2023December 2025Abandon3401NoNo
18103768Method and System to Reduce the Likelihood of Dental Caries and HalitosisJanuary 2023July 2023Allow610NoNo
18040079PROBIOTIC SYSTEM AND USE THEREOFJanuary 2023November 2025Allow3411YesNo
18158047Methods and Compositions for Treatment of Microbiome Associated DisordersJanuary 2023July 2024Allow1810NoNo
18017307PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE CONTAINING FAECALIBACTERIUM PRAUSNITZII STRAINJanuary 2023February 2026Allow3620YesNo
18151205Compositions and Methods for the Treatment of Hepatic Diseases and DisordersJanuary 2023February 2025Allow2611NoNo
18146783HYBRIDOMA CELL LINE OF SECRETING CYPROHEPTADINE MONOCLONAL ANTIBODIES AND PREPARATION METHOD THEREOFDecember 2022December 2024Allow2430YesNo
18087545Topical Application of Lactobacillus Crispatus to Ameliorate Barrier Damage and InflammationDecember 2022July 2023Allow710YesNo
18003012ANTI-PD1 ANTIBODIES AND USES THEREOFDecember 2022March 2026Abandon3810NoNo
18069535BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANINDecember 2022November 2025Abandon3510NoNo
18010170TREATMENT OF FOOD ALLERGY USING ANTI-IGE ANTIBODIESDecember 2022February 2026Abandon3810NoNo
17913749MODIFIED CHANNELRHODOPSINDecember 2022August 2025Allow3410NoNo
18073824TREATMENT OF SEVERE COMMUNITY ACQUIRED PNEUMONIADecember 2022August 2024Allow2110NoNo
18074122BACTERIAL EXTRACELLULAR VESICLESDecember 2022May 2024Allow1810NoNo
18072841LIQUID PHARMACEUTICAL COMPOSITIONDecember 2022June 2024Abandon1901NoNo
18072852LIQUID PHARMACEUTICAL COMPOSITIONDecember 2022November 2024Abandon2410NoNo
18057957MDR E. COLI IMMUNOGENNovember 2022December 2024Allow2522YesNo
17982067FASTING-MIMICKING DIET (FMD) BUT NOT WATER-ONLY FASTING PROMOTES REVERSAL OF INFLAMMATION AND IBD PATHOLOGYNovember 2022August 2024Allow2211NoNo
17981262CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATIONNovember 2022February 2025Allow2820NoNo
17922960METHODS FOR DIAGNOSING AND TREATING METABOLIC DISEASESNovember 2022October 2025Abandon3601NoNo
17922499LIVE SELF-DESTRUCTING BACTERIAL ADJUVANTS TO ENHANCE INDUCTION OF IMMUNITYOctober 2022December 2025Allow3711NoNo
18048631DONOR REPAIR TEMPLATES MULTIPLEX GENOME EDITINGOctober 2022October 2025Allow3610NoNo
17996720COMPOSITION FOR USE IN THE TREATMENT OF GROUP-B STREPTOCOCCUS (GBS) INFECTIONSOctober 2022September 2025Allow3510NoNo
17996779COMPOSITIONS AND METHODS COMPRISING CLOSTRIDIUM BUTYRICUM FOR THE TREATMENT OF CANCEROctober 2022December 2025Allow3711NoNo
17919734A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASESOctober 2022February 2026Abandon4001NoNo
17938865ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOFOctober 2022January 2024Allow1500NoNo
17917531CHARGE VARIANT LINKERSOctober 2022January 2026Abandon4001NoNo
17937819COMBINATION THERAPY FOR TREATING OR PREVENTING CANCEROctober 2022April 2024Abandon1810NoNo
17952990TARS DERIVED FROM AKKERMANSIA MUCINIPHILA OR FRAGMENT THEREOF, AND USE THEREOFSeptember 2022February 2026Allow4011NoNo
17907054USE OF BY-PRODUCTS FROM THE ALCOHOLIC BEVERAGE MANUFACTURING INDUSTRYSeptember 2022November 2025Allow3810YesNo
17910975SHEDDING BLOCKING AGENTS WITH INCREASED STABILITYSeptember 2022December 2025Allow3910NoNo
17909917A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS SEROTYPE 9, SEQUENCE TYPE 16September 2022April 2025Allow3101NoNo
17908703CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERSeptember 2022November 2025Allow3910NoNo
17904998DIGESTIVE ENZYME AGENTAugust 2022February 2026Abandon4210NoNo
17905001COMPOSITIONS AND METHODS FOR REDUCING CYTOKINE EXPRESSIONAugust 2022September 2025Abandon3710NoNo
17893384Method and System for Reducing the Likelihood of OsteoporosisAugust 2022August 2023Allow1210YesNo
17801786NOVEL ANTIBODIESAugust 2022December 2025Allow4001NoNo
17820252COMPOSITIONS COMPRISING BACTERIAL STRAINSAugust 2022May 2024Abandon2101NoNo
17820029METHODS FOR TREATING AND FOR INHIBITING PROGRESSION OF SEIZURESAugust 2022December 2025Abandon4010NoNo
17798420CUTIBACTERIUM ACNES STRAIN AND MEDICAL USES THEREOFAugust 2022August 2025Allow3710NoNo
17879700COMPOSITION FOR USE IN THE TREATMENT AND/OR IMPROVEMENT OF SLEEP AND MOOD DISORDERSAugust 2022October 2023Allow1510NoNo
17815705BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, METHODS OF PRODUCTION THEREOF, AND METHODS OF USE THEREOFJuly 2022October 2023Allow1500NoNo
17874846Capture Purification Processes for Proteins Expressed in a Non-Mammalian SystemJuly 2022January 2025Allow3010NoNo
17758379METHODS FOR IDENTIFYING ANTI CLOSTRIDIAL NEUROTOXIN COMPOUNDSJuly 2022October 2025Allow4001YesNo
17857614LOCALIZED IMMUNOSUPPRESSION OF ALLOGRAFTS FOR PERIPHERAL NERVE REPAIRJuly 2022April 2025Allow3400NoNo
17856013METHODS AND COMPOSITIONS FOR THE TREATMENT OF C. DIFFICILEJuly 2022September 2023Allow1500NoNo
17854422Method for Treating Individuals Having Cancer and who are Receiving Cancer ImmunotherapyJune 2022February 2023Allow820NoNo
17853134Anti-TIGIT AntibodiesJune 2022January 2024Abandon1801NoNo
17850422VACCINE TO PREVENT MYCOPLASMAL INFECTIONS IN WATERFOWLJune 2022February 2024Allow2000NoNo
17848759Method for Treating an Individual Suffering from Bladder CancerJune 2022December 2022Allow610NoNo
17835204Method and System for Reducing the Likelihood of Developing Colorectal Cancer in an Individual Human BeingJune 2022August 2022Allow210NoNo
17832487MICROORGANISMS ENGINEERED TO REDUCE HYPERPHENYLALANINEMIAJune 2022June 2023Allow1311YesNo
17664156ALTERING THE INTESTINAL MICROBIOME IN CYSTIC FIBROSISMay 2022October 2024Allow2920NoNo
17737513Compositions and Methods for Treating the EyeMay 2022September 2023Allow1610NoNo
17727129MICROBIAL CONSORTIAApril 2022June 2024Abandon2601NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GANGLE, BRIAN J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
8
Examiner Affirmed
7
(87.5%)
Examiner Reversed
1
(12.5%)
Reversal Percentile
24.6%
Lower than average

What This Means

With a 12.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
56
Allowed After Appeal Filing
6
(10.7%)
Not Allowed After Appeal Filing
50
(89.3%)
Filing Benefit Percentile
13.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 10.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GANGLE, BRIAN J - Prosecution Strategy Guide

Executive Summary

Examiner GANGLE, BRIAN J works in Art Unit 1645 and has examined 1,020 patent applications in our dataset. With an allowance rate of 70.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner GANGLE, BRIAN J's allowance rate of 70.8% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by GANGLE, BRIAN J receive 1.68 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GANGLE, BRIAN J is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.9% benefit to allowance rate for applications examined by GANGLE, BRIAN J. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.4% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 64.0% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 73.3% of appeals filed. This is in the 62% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 62.2% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.1% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.4% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.